NewAmsterdam Pharma Co N.V. (NAMS) · Aug 14, 2026 · Exec change

New accounting chief fills a gap the market already knew was coming

Accounting officer appointed — Gunning succeeds Louise Kooij, whose August 31 departure was previously announced

Robert Gunning replaces the departing principal accounting officer, but the transition was already disclosed and carries no earnings or guidance signal.

The transition was already on the market’s radar. Louise Kooij’s departure effective August 31 had been previously announced, so the core change is confirmation rather than a fresh surprise. 〔0〕

The filing names a replacement, but offers no operating signal. Robert W. Gunning became vice president, controller and principal accounting officer on August 10; the filing provides his prior biopharma finance experience but does not change earnings expectations, guidance, strategy, or capital plans. 〔1〕

Compensation is standard hiring detail, not a market-moving datapoint. Gunning will receive a $375,000 base salary, a 30% target annual bonus, 3,200 restricted stock units, and an option for 14,000 shares, with the full offer letter expected in the September 30 quarterly report. (Offer Letter)

Net read: routine and neutral. There is no clean consensus benchmark for an accounting-officer appointment, but versus the standing expectation of a planned succession, this filing is essentially in line: continuity has been established, with no disclosed complication or incremental financial surprise.

Original filing on SEC EDGAR

More NewAmsterdam Pharma Co N.V. news

New accounting chief fills a gap the market already knew was coming | NAMS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.